Roivant Starts Commercial Drug Sales With $31.0 Million — Shareholder Loss Widens
LISRAYA’s launch raised selling costs, while arthritis, eye-disease and lung-disease trials advanced.
Roivant Sciences, which develops and sells medicines through drug-focused subsidiaries, recorded $31.0 million in LISRAYA sales during its first five launch weeks, but its second-quarter loss attributable to shareholders widened. The company’s earnings release, attached to Monday’s SEC filing, puts that loss at $191.6 million, versus $113.5 million a year earlier.
LISRAYA Revenue Meets Launch Costs
LISRAYA, the brand name for brepocitinib, became available in the U.S. after August 2026 FDA approval to treat adults with dermatomyositis. Roivant had no product revenue in the year-earlier quarter; the launch moves its subsidiary-based drug-development business into commercial sales.
Selling and administrative spending reached $154.1 million, compared with $143.1 million a year earlier, primarily because of the launch. Research spending fell to $145.7 million from $164.6 million, with lower personnel costs and reduced spending on Immunovant programs partly offset by mosliciguat’s development.
The wider shareholder loss included $95.9 million of distributions to holders of Genevant equity awards that participated in the Moderna settlement payout. Across continuing operations, the after-tax loss narrowed to $153.0 million from $166.0 million; the adjusted loss narrowed to $133.4 million from $187.8 million.
Arthritis Success Has A Dose Split
Immunovant’s IMVT-1402 antibody met the rheumatoid arthritis trial’s main goal at 600 mg. The comparison covered patients who had already responded to treatment and were randomly assigned to keep receiving the drug or switch to placebo: 92.5% maintained the specified response at Week 28, versus 75.6% on placebo. The 300 mg group showed no difference from placebo.
Roivant CEO Matt Gline said the broader results support the drug’s potential to “maintain and deepen responses” in patients who had failed multiple advanced therapies. Immunovant plans FDA discussions later this year about the approval program, but further development for Sjögren’s disease beyond its fully enrolled mid-stage trial is unlikely, the company said.
Brepocitinib also met the main and all key secondary goals in both late-stage trials for non-infectious uveitis. At Week 48, 62% of treated patients had inactive disease without steroids, against 20% receiving placebo. Priovant intends to apply for expanded approval in the first half of 2027.
Pulmovant began enrolling a late-stage mosliciguat trial for pulmonary hypertension associated with interstitial lung disease after positive mid-stage results. That study showed a placebo-adjusted 56.3% reduction in resistance to blood flow through the lungs at Week 16, alongside a 35.2-meter improvement in six-minute walking distance.
Settlement Cash And Share Buybacks
Roivant held $4.2 billion in cash, cash equivalents and marketable securities as of September 30, 2026, an amount management says can fund operations through profitability. During the quarter, it bought back 2.1 million shares for approximately $72.5 million.
The cash balance includes July’s initial $950 million payment from Moderna to Genevant and Arbutus under their $2.25 billion patent settlement. Another $1.3 billion depends on a resolution of Moderna’s appeal favorable to Genevant and Arbutus; oral arguments took place Thursday. The separate Pfizer/BioNTech case remains ongoing.
Roivant is scheduled to hold an investor day on December 9, 2026, in New York City and virtually.
Sources
- 8-K Filing — Roivant Sciences Ltd. (ROIV) — SEC EDGAR
- Exhibit q2fy2026roivantearningsrel.htm — Roivant Sciences Ltd. 8-K exhibit — SEC EDGAR
- Roivant Reports Financial Results for the Second Quarter — globenewswire.com